Business Context and Reporting Period
This Form 8-K, dated January 4, 2018, reports the completion of a merger between Inotek Pharmaceuticals Corporation and Rocket Pharmaceuticals, Ltd. Following the transaction, the company changed its name to Rocket Pharmaceuticals, Inc. The business focus shifted to Rocket's multi-platform biotechnology operations, specifically the development of first-in-class gene therapies for rare pediatric diseases. The company remains listed on the NASDAQ under the new ticker symbol "RCKT" (previously "ITEK").
Key Financial Metrics and Capital Structure
The filing details the capital structure resulting from the merger but does not provide specific revenue, profit, or cash flow figures for the combined entity in this document; such data is referenced in the Proxy Statement.
- Stock Issuance: 26,272,107 shares of common stock were issued to Rocket shareholders.
- Exchange Ratio: Approximately 76.185 shares of the Company's common stock for each share of Rocket share capital.
- Ownership Post-Merger: Former Inotek shareholders own approximately 18.643% (fully diluted); former Rocket shareholders own approximately 81.357% (fully diluted).
- Reverse Stock Split: A 1-for-4 reverse stock split was implemented, resulting in approximately 33.1 million shares outstanding post-split.
- Debt: The company has 5.75% Convertible Senior Notes due 2021, which were adjusted for the reverse stock split.
- Lock-Up Agreements: Certain shareholders (approx. 5% of Inotek and 62.1% of Rocket) agreed to lock-up periods of 180 days.
Material Changes Versus Prior Period
The most significant change is the fundamental shift in corporate identity and control. The company transitioned from Inotek Pharmaceuticals Corporation to Rocket Pharmaceuticals, Inc., with Rocket shareholders becoming the majority owners. The board of directors and executive officers were entirely reconstituted. The trading symbol changed from "ITEK" to "RCKT," and the CUSIP number was updated to 77313F 106.
Guidance, Outlook, and Management Commentary
Management Changes:
- CEO: Gaurav Shah appointed President and CEO (Base Salary: $331,500; Target Bonus: $125,000).
- CMO: Jonathan Schwartz appointed Chief Medical Officer (Base Salary: $348,098; Target Bonus: 33%).
- CFO: Brian Batchelder appointed VP of Finance, Chief Accounting Officer, Treasurer, and Secretary (Base Salary: $202,334; Target Bonus: 25%).
- COO: Kinnari Patel appointed Chief Operating Officer (Base Salary: $285,000; Target Bonus: 33%).
Outlook: The company is now focused on Rocket's pipeline of gene therapies. The filing notes that the company intends to enter into new employment agreements with the executive officers.
Risks and Contingencies: The filing references the assumption of Rocket's share option plans and the adjustment of existing Inotek options and convertible notes. Fractional shares from the reverse split were settled in cash based on the average last reported sales price over 10 trading days prior to the effective date.
Important Facts for Investor Verification
- Verify the pro forma financial information and audited financial statements of Rocket Pharmaceuticals, Ltd., which are incorporated by reference in the Proxy Statement (Pages F-3 and F-24).
- Confirm the exact number of shares outstanding (approx. 33.1 million post-split) and the impact of the 1-for-4 reverse split on existing holdings.
- Review the terms of the 5.75% Convertible Senior Notes due 2021 to understand the adjusted conversion rates and exercise prices.
- Check the 180-day lock-up expiration dates for the significant shareholders holding approximately 62.1% of the former Rocket equity.
- Monitor the status of the new executive team's employment agreements and the integration of Rocket's R&D pipeline.